Matthew Fan

Finance Controller China AA @ AbbVie

About

Based in Shanghai, I lead finance for AbbVie–Allergan China’s device-heavy aesthetics business with five consecutive clean SOX cycles and four Green internal audits. I’ve delivered OP margin expansion via transfer pricing optimization (+5 ppts), established an FTZ device trading entity (+4 ppts OP; >$60m over 5 years), reset Tier-1 distributor margin from 7.5%→2.5% (+3 ppts OP), lifted net price by +100 bps, cut DSO by 10 days, and secured RMB 30m/year in government subsidies. Previously at GSK, I turned a BU from negative to +13.6% OP and delivered £23.3m A&P savings. I’m targeting China Country CFO roles in medtech/devices and healthcare services. Non-relocating.

Country

China

City

Huangpu District

Industry

Pharmaceuticals

Skill

财务领导力, 业务转型, SOX 404, Analysis, Finance, Budget, Forecast, Leadership, Management, Change management, Project management, Pharmaceutical Industry, Business Planning, Training, Presentation, Financial Analysis, Auditing, Internal Control, Consumer Health Industry, R&D

Experience

Finance Controller China AA

AbbVie

2021-4 - Present · 5 yrs 6 mos

Shanghai

Directed end-to-end controllership for 4 China legal entities (+1 offshore) in a device-heavy aesthetics portfolio with B2B hospital/clinic and B2C channels; SOX: 5 consecutive clean cycles; Internal Audit: 4 consecutive Green ratings (best ever). Chaired China Audit Committee; zero repeat findings. Transfer Pricing optimization (2025): OP margin +5 percentage points; strengthened TP documentation, variance monitoring, and governance; zero tax penalties. Source-to-Pay and T&E transformation: invoice cycle time −45%; policy exceptions −78%; late-payment penalties eliminated. Cash & treasury: thin-cap management across 4 LEs, cash pooling governance, distributor credit-limit reviews and collections cadence; cash conversion cycle −10 days driven by DSO −10 days. Tax ownership: daily customs/VAT approvals for device imports; monthly VAT/IIT reviews; quarterly stamp duty and CIT reviews; annual CIT sign-off; managed inspections and regulator inquiries with clean outcomes. Government incentives: secured RMB 30m/year recurring subsidies; implemented renewal calendar and audit trail. Distributor governance: led distributor selection, annual performance & credit reviews; embedded deal desk and pricing guardrails to de-risk channel economics.

FP&A Lead China AA

AbbVie

2019-2 - 2021-3 · 2 yrs 2 mos

Shanghai, China

Established FTZ trading entity for medical devices (2019): >$60m cumulative margin benefit over five years via duty/consumption-tax optimization and improved supply control; OP margin +4 percentage points. NRM/Channel reset: negotiated Tier-1 distributor margin from 7.5% → 2.5%, lifting OP margin by +3 percentage points; instituted GTN discipline and leakage controls. Pricing programs: net price realization +100 bps via pricing and GTM initiatives; improved hospital/clinic deal approval rigor. COVID-19 resilience: recovery KPIs and scenario planning; strengthened forecast quality; contributed to CCC −10 days via DSO improvement; supported launches and market-access milestones.

Finance Head of BU

GSK

2013-7 - 2019-2 · 5 yrs 8 mos

Shanghai

Finance Head – Oral/Stiefel BU (2016–2017): turned BU from negative to +13.6% OP (2017) via mix, trade terms, and EC/CBEC scaling; executed national barcode transition (19 SKUs, 200+ distributors, 11 NKAs) with zero returns; supported JV integration and SAP rollout. Finance Head – Greater China Commercial Excellence (2017–2019): A&P savings £23.3m (Fill-for-Growth); +£28m net sales over 3 years via pricing and trade spend efficiency; secured 2018 Pricing £9.4m and GTN optimization £9.3m. Finance Lead – R&D/CCT & CE (2014–2016) and Rx/Vx FP&A Lead (2013): institutionalized NPI finance model/governance; streamlined planning and reporting; finance capability facilitator for 150+ staff.